| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.
|
Mov Disord
|
2004
|
4.83
|
|
2
|
Association between stroke center hospitalization for acute ischemic stroke and mortality.
|
JAMA
|
2011
|
3.68
|
|
3
|
Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients.
|
Crit Care Med
|
2007
|
2.76
|
|
4
|
A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association.
|
Stroke
|
2009
|
2.74
|
|
5
|
Financial anatomy of neuroscience research.
|
Ann Neurol
|
2006
|
2.71
|
|
6
|
Financing of U.S. biomedical research and new drug approvals across therapeutic areas.
|
PLoS One
|
2009
|
1.55
|
|
7
|
Health state preferences and decision-making after malignant middle cerebral artery infarctions.
|
Neurology
|
2010
|
1.52
|
|
8
|
An approach to evaluating the therapeutic misconception.
|
IRB
|
2009
|
1.35
|
|
9
|
Evidence, preferences, recommendations--finding the right balance in patient care.
|
N Engl J Med
|
2012
|
1.26
|
|
10
|
Palliative and end-of-life care in stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
|
Stroke
|
2014
|
1.17
|
|
11
|
The evolving role and value of libraries and librarians in health care.
|
JAMA
|
2013
|
1.07
|
|
12
|
Early stroke mortality, patient preferences, and the withdrawal of care bias.
|
Neurology
|
2012
|
1.07
|
|
13
|
The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
|
Med Decis Making
|
2007
|
1.03
|
|
14
|
Symptomatic and palliative care for stroke survivors.
|
J Gen Intern Med
|
2012
|
1.02
|
|
15
|
Development and testing of the Parkinson's disease quality of life scale.
|
Mov Disord
|
2003
|
1.01
|
|
16
|
Research participants' "irrational" expectations: common or commonly mismeasured?
|
IRB
|
2013
|
1.00
|
|
17
|
Treatment decisions after severe stroke: uncertainty and biases.
|
Stroke
|
2012
|
1.00
|
|
18
|
CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes.
|
Radiology
|
2002
|
0.99
|
|
19
|
Risk adjustment of ischemic stroke outcomes for comparing hospital performance: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
|
Stroke
|
2014
|
0.97
|
|
20
|
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
|
Neurology
|
2007
|
0.97
|
|
21
|
Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model.
|
J Womens Health (Larchmt)
|
2009
|
0.97
|
|
22
|
Funding of Parkinson research from industry and US federal and foundation sources.
|
Mov Disord
|
2009
|
0.96
|
|
23
|
Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals.
|
Am Heart J
|
2010
|
0.95
|
|
24
|
Palliative Care Needs in the Neuro-ICU.
|
Crit Care Med
|
2015
|
0.95
|
|
25
|
Racial differences in mortality among patients with acute ischemic stroke: an observational study.
|
Ann Intern Med
|
2011
|
0.95
|
|
26
|
Ethics of sham surgery: perspective of patients.
|
Mov Disord
|
2008
|
0.92
|
|
27
|
Hemicraniectomy for middle-cerebral-artery stroke.
|
N Engl J Med
|
2014
|
0.92
|
|
28
|
Challenges in assessing hospital-level stroke mortality as a quality measure: comparison of ischemic, intracerebral hemorrhage, and total stroke mortality rates.
|
Stroke
|
2012
|
0.91
|
|
29
|
Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysis.
|
Am J Psychiatry
|
2003
|
0.91
|
|
30
|
Reading a cost-effectiveness or decision analysis study: Five things to consider.
|
Neurol Clin Pract
|
2013
|
0.90
|
|
31
|
Variation in do-not-resuscitate orders for patients with ischemic stroke: implications for national hospital comparisons.
|
Stroke
|
2014
|
0.90
|
|
32
|
Trust in early phase research: therapeutic optimism and protective pessimism.
|
Med Health Care Philos
|
2008
|
0.88
|
|
33
|
Comparison of enrollees and decliners of Parkinson disease sham surgery trials.
|
Mov Disord
|
2012
|
0.87
|
|
34
|
Public reporting of quality data for stroke: is it measuring quality?
|
Stroke
|
2008
|
0.85
|
|
35
|
Parkinson's disease medication use and costs following deep brain stimulation.
|
Mov Disord
|
2012
|
0.84
|
|
36
|
Biomarkers in Parkinson's disease.
|
Expert Rev Neurother
|
2006
|
0.84
|
|
37
|
A cost-effectiveness analysis of carotid artery stenting compared with endarterectomy.
|
J Stroke Cerebrovasc Dis
|
2010
|
0.84
|
|
38
|
A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
|
J Am Geriatr Soc
|
2007
|
0.83
|
|
39
|
Sham surgery controls in Parkinson's disease clinical trials: views of participants.
|
Mov Disord
|
2012
|
0.83
|
|
40
|
Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.
|
Value Health
|
2006
|
0.80
|
|
41
|
What is the risk of developing parkinsonism following neuroleptic use?
|
Neurology
|
2006
|
0.80
|
|
42
|
Ethical considerations in stroke patients.
|
Curr Opin Neurol
|
2014
|
0.80
|
|
43
|
Surrogate endpoints in Parkinson's disease research.
|
Curr Neurol Neurosci Rep
|
2003
|
0.80
|
|
44
|
Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
|
Pharmacoeconomics
|
2005
|
0.80
|
|
45
|
Diffusion tensor imaging: scientific advance, clinical tool, or just a pretty picture?
|
Neurology
|
2007
|
0.80
|
|
46
|
A review of pramipexole and its clinical utility in Parkinson's disease.
|
Expert Opin Pharmacother
|
2002
|
0.80
|
|
47
|
Pearls & Oy-sters: a stroke of luck: detecting type A aortic dissection by MRA.
|
Neurology
|
2011
|
0.79
|
|
48
|
A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
|
Pharmacoeconomics
|
2008
|
0.79
|
|
49
|
Evidence from cost-effectiveness research.
|
NeuroRx
|
2004
|
0.79
|
|
50
|
Patient Preferences and Surrogate Decision Making in Neuroscience Intensive Care Units.
|
Neurocrit Care
|
2015
|
0.77
|
|
51
|
Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites.
|
Mov Disord
|
2014
|
0.77
|
|
52
|
Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
|
Med Decis Making
|
2004
|
0.77
|
|
53
|
Responsiveness of life-threatening refractory emesis to gabapentin-scopolamine therapy following posterior fossa surgery. Case report.
|
J Neurosurg
|
2005
|
0.76
|
|
54
|
Could the High Prevalence of Therapeutic Misconception Partly Be a Measurement Problem?
|
IRB
|
2015
|
0.76
|
|
55
|
Is it research?: an increasingly common question.
|
Neurology
|
2010
|
0.76
|
|
56
|
Too important to fail.
|
Ann Neurol
|
2013
|
0.75
|
|
57
|
When disclosures are more interesting than the evidence.
|
Stroke
|
2008
|
0.75
|
|
58
|
Quality of life in epilepsy, multiple sclerosis, and beyond.
|
Ann Neurol
|
2007
|
0.75
|
|
59
|
There is nothing staid about STARD: progress in the reporting of diagnostic accuracy studies.
|
Neurology
|
2006
|
0.75
|
|
60
|
Review: noninvasive imaging techniques may be useful for diagnosing 70% to 99% carotid stenosis in symptomatic patients.
|
ACP J Club
|
2006
|
0.75
|
|
61
|
How much is a good night's sleep worth?
|
Stroke
|
2005
|
0.75
|
|
62
|
Evidence-based neurotherapeutics: a spectrum of evidence.
|
NeuroRx
|
2004
|
0.75
|
|
63
|
Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
|
Neurology
|
2005
|
0.75
|
|
64
|
Evidence-based research ethics and determinations of "engagement in research".
|
IRB
|
2014
|
0.75
|
|
65
|
Patient and organizational factors related to education and support use by Veterans with Parkinson's disease.
|
Mov Disord
|
2009
|
0.75
|
|
66
|
Raising the Alarm on Brain Attacks in Surgical Patients: Are We Doing Enough to Prevent and Treat Postoperative Strokes?
|
Anesthesiology
|
2017
|
0.75
|